Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations.

Fernandez AP, Sun Y, Tubbs RR, Goldblum JR, Billings SD.

J Cutan Pathol. 2012 Feb;39(2):234-42. doi: 10.1111/j.1600-0560.2011.01843.x. Epub 2011 Nov 29.

PMID:
22121953
2.

Fully automated dual-color dual-hapten silver in situ hybridization staining for MYC amplification: a diagnostic tool for discriminating secondary angiosarcoma.

Ko JS, Billings SD, Lanigan CP, Buehler D, Fernandez AP, Tubbs RR.

J Cutan Pathol. 2014 Mar;41(3):286-92. doi: 10.1111/cup.12278. Epub 2014 Jan 22.

PMID:
24329959
3.

Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites.

Ginter PS, Mosquera JM, MacDonald TY, D'Alfonso TM, Rubin MA, Shin SJ.

Hum Pathol. 2014 Apr;45(4):709-16. doi: 10.1016/j.humpath.2013.11.002. Epub 2013 Nov 12.

PMID:
24457083
4.

Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression.

Fraga-Guedes C, André S, Mastropasqua MG, Botteri E, Toesca A, Rocha RM, Peradze N, Rotmensz N, Viale G, Veronesi P, Gobbi H.

Breast Cancer Res Treat. 2015 May;151(1):131-40. doi: 10.1007/s10549-015-3379-2. Epub 2015 Apr 19.

PMID:
25893585
5.

The utility of MYC and FLT4 in the diagnosis and treatment of postradiation atypical vascular lesion and angiosarcoma of the breast.

Cornejo KM, Deng A, Wu H, Cosar EF, Khan A, St Cyr M, Tomaszewicz K, Dresser K, O'Donnell P, Hutchinson L.

Hum Pathol. 2015 Jun;46(6):868-75. doi: 10.1016/j.humpath.2015.02.014. Epub 2015 Mar 10.

PMID:
25864386
6.

MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study.

Shon W, Sukov WR, Jenkins SM, Folpe AL.

Mod Pathol. 2014 Apr;27(4):509-15. doi: 10.1038/modpathol.2013.163. Epub 2013 Oct 4.

7.

Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions.

Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR.

Genes Chromosomes Cancer. 2011 Jan;50(1):25-33. doi: 10.1002/gcc.20827.

9.
10.

Post-radiotherapy vascular proliferations in mammary skin: a clinicopathologic study of 11 cases.

Mattoch IW, Robbins JB, Kempson RL, Kohler S.

J Am Acad Dermatol. 2007 Jul;57(1):126-33.

PMID:
17572278
11.

MYC amplification in angiosarcomas arising in the setting of chronic lymphedema of morbid obesity.

Harker D, Jennings M, McDonough P, Mauskar M, Savory S, Hosler GA, Vandergriff T.

J Cutan Pathol. 2017 Jan;44(1):15-19. doi: 10.1111/cup.12827. Epub 2016 Oct 21.

PMID:
27686553
12.

MYC Analysis by Fluorescent In Situ Hybridization and Immunohistochemistry in Primary Adrenal Angiosarcoma (PAA): a Series of Four Cases.

Cornejo KM, Hutchinson L, Cyr MS, Nose V, McLaughlin PJ, Iafrate AJ, Sadow PM.

Endocr Pathol. 2015 Dec;26(4):334-41. doi: 10.1007/s12022-015-9385-4.

PMID:
26223194
13.
14.

MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema.

Manner J, Radlwimmer B, Hohenberger P, Mössinger K, Küffer S, Sauer C, Belharazem D, Zettl A, Coindre JM, Hallermann C, Hartmann JT, Katenkamp D, Katenkamp K, Schöffski P, Sciot R, Wozniak A, Lichter P, Marx A, Ströbel P.

Am J Pathol. 2010 Jan;176(1):34-9. doi: 10.2353/ajpath.2010.090637. Epub 2009 Dec 11.

16.

MYC immunohistochemistry in angiosarcoma and atypical vascular lesions: practical considerations based on a single institutional experience.

Udager AM, Ishikawa MK, Lucas DR, McHugh JB, Patel RM.

Pathology. 2016 Dec;48(7):697-704. doi: 10.1016/j.pathol.2016.08.007. Epub 2016 Oct 22.

PMID:
27780597
17.

Tumour suppressor gene TP53 mutations in atypical vascular lesions of breast skin following radiotherapy.

Santi R, Cetica V, Franchi A, Pepi M, Cesinaro AM, Miracco C, Paglierani M, De Giorgi V, Delfino C, Difonzo EM, Pimpinelli N, Bianchi S, Sardi I, Santucci M, Massi D.

Histopathology. 2011 Feb;58(3):455-66. doi: 10.1111/j.1365-2559.2011.03770.x. Epub 2011 Feb 16.

PMID:
21323968
18.

Can c-myc amplification reliably discriminate postradiation from primary angiosarcoma of the breast?

Laé M, Lebel A, Hamel-Viard F, Asselain B, Trassard M, Sastre X, Kirova YM.

Cancer Radiother. 2015 May;19(3):168-74. doi: 10.1016/j.canrad.2015.01.001. Epub 2015 Apr 8.

PMID:
25863565
19.

Clinicopathological and immunohistochemical study of 30 cases of post-radiation atypical vascular lesion of the breast.

Fraga-Guedes C, Gobbi H, Mastropasqua MG, Rocha RM, Botteri E, Toesca A, Viale G.

Breast Cancer Res Treat. 2014 Jul;146(2):347-54. doi: 10.1007/s10549-014-3020-9. Epub 2014 Jun 19.

PMID:
24943869
20.

The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification.

Italiano A, Thomas R, Breen M, Zhang L, Crago AM, Singer S, Khanin R, Maki RG, Mihailovic A, Hafner M, Tuschl T, Antonescu CR.

Genes Chromosomes Cancer. 2012 Jun;51(6):569-78. doi: 10.1002/gcc.21943. Epub 2012 Mar 2.

Supplemental Content

Support Center